Drugs / Astrazenica vaccine
Astrazenica vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05017792 | Aug 2021 → Sep 2022 | COVID-19 | Samia Hassan El-Shishtawy | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Astrazenica vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05017792 ↗ |
| Known as | AstraZeneca COVID-19 vaccines | “The UK government recently decided to extend the interval between the first dose of the Pfizer BioNTech and AstraZeneca COVID-19 vaccines from 3 weeks to 12 weeks” NCT05017792 ↗ |
| Known as | AstrazenicaCovid 19 vaccine | “Evaluation of the efficacy of the AstrazenicaCovid 19 vaccine to develop IgG antibody” NCT05017792 ↗ |
| Modality | Vaccine | “AstrazenicaCovid 19 vaccine” NCT05017792 ↗ |